Back to top
more

Eli Lilly (LLY)

(Real Time Quote from BATS)

$889.56 USD

889.56
860,892

+5.08 (0.57%)

Updated Oct 2, 2024 01:20 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 17% (44 out of 252)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Zacks Industry Outlook Highlights: H. Lundbeck, Eli Lilly, GlaxoSmithKline and Novartis

Zacks Industry Outlook Highlights: H. Lundbeck, Eli Lilly, GlaxoSmithKline and Novartis

    Pharma Stock Roundup: LLY/AZN Alzheimer's Drug Fails, MRK's Keytruda Wins Approvals

    Eli Lilly (LLY)/AstraZeneca (AZN) discontinue two late-stage studies on Alzheimer's disease candidate, lanabecestat. Merck's Keytruda gets FDA nod for two new indications.

      Allergan (AGN) Presents Positive Data on Glaucoma Candidate

      Allergan (AGN) posts positive top-line data from a phase III study on Bimatoprost SR, a biodegradable implant for reducing IOP in patients with open-angle glaucoma or ocular hypertension.

        Merck's Keytruda Gets FDA Nod for 2nd Lymphoma Indication

        Merck's (MRK) Keytruda gets FDA approval for primary mediastinal B-cell lymphoma (PMBCL) - its second label expansion approval this week.

          J&J (JNJ) Accepts Platinum Equity's Offer for LifeScan Unit

          Johnson & Johnson (JNJ) to sell its LifeScan diabetes device unit to Platinum Equity.

            Lilly & AstraZeneca Scrap Studies on Alzheimer's Candidate

            Eli Lilly (LLY) and AstraZeneca (AZN) are discontinuing two late-stage studies on their Alzheimer's disease candidate, lanabecestat.

              Allergan's Second Anti-CGRP Drug Positive in Mid-Stage Study

              Allergan's (AGN) anti-CGRP candidate, atogepant, successful in mid-stage study, following positive data readouts from two phase III studies on another anti-CGRP candidate, ubrogepant.

                Kinjel Shah headshot

                Alzheimer's Research Stumbles Again: What's the Road Ahead?

                The discontinuation of Lilly/AstraZeneca's two late-stage studies on their Alzheimer's disease candidate, lanabecestat adds to a long list of failed treatment options for this deadly brain disease.

                  AstraZeneca's Tagrisso Wins EU Nod for First-Line Lung Cancer

                  AstraZeneca's (AZN) Tagrisso gets an EU nod for first-line treatment of advanced or metastatic non-small cell lung cancer in patients with epidermal growth factor receptor (EGFR) mutations.

                    Abbvie/Roche's Leukemia Drugs Combination Gets FDA Approval

                    AbbVie (ABBV) and Roche's (RHHBY) cancer drugs, Venclexta and Rituxan receive approval for combination use in second-line chronic lymphocytic leukemia.

                      Amgen's (AMGN) Prolia Gets Label Expansion Approval in Europe

                      Amgen (AMGN) announces approval for its regulatory application seeking label expansion for Prolia in Europe.

                        Indrajit Bandyopadhyay headshot

                        JAK Inhibitors' Prospects Strong: 4 Stocks Ruling the Space

                        Given the growing interest in JAK-inhibitor based treatments, here's a look at some companies that are looking to change the ways to treat autoimmune diseases.

                          The Zacks Analyst Blog Highlights: Bristol Myers, Merck, Roche, Lilly and AbbVie

                          The Zacks Analyst Blog Highlights: Bristol Myers, Merck, Roche, Lilly and AbbVie

                            Pfizer Boosts Venture Capital Efforts, Neuroscience in Focus

                            Pfizer (PFE) to pour $600 million in its venture capital arm. About 150 million will be earmarked for companies involved in promising early-stage neuroscience research.

                              J&J Receives Buyout Offer for Sterilization Products Unit

                              Johnson & Johnson (JNJ) receives a binding offer worth $2.8 billion from Fortive Corporation for its sterilization products business.

                                Abbvie's (ABBV) Upadacitinib Fifth RA Study Data Positive

                                AbbVie (ABBV) announces positive top-line results from the fifth phase III study on its JAK inhibitor, upadacitinib in moderate-to-severe rheumatoid arthritis.

                                  Merck Presents Positive Melanoma Data on Keytruda at ASCO

                                  Merck (MRK) presents encouraging data from two pivotal advanced melanoma studies on its PD-L1 inhibitor, Keytruda.

                                    Eli Lilly's Olumiant Gets FDA Nod for Rheumatoid Arthritis

                                    Eli Lilly (LLY) and its partner Incyte announce approval of their arthritis drug, Olumiant, in the United States. The drug will be available at two-fifth of the price of leading RA drugs.

                                      Merck's (MRK) Keytruda Lung Cancer Data in Focus at ASCO

                                      Merck (MRK) presents data from several cancer studies of its PD-L1 inhibitor, Keytruda at ASCO including two key lung cancer trials.

                                        The Zacks Analyst Blog Highlights: Chevron, Wells Fargo, Eli Lilly, FedEx and Valero

                                        The Zacks Analyst Blog Highlights: Chevron, Wells Fargo, Eli Lilly, FedEx and Valero

                                          Allergan Recalls Taytulla Oral Contraceptives, Stock Down

                                          Allergan (AGN) recalls some sample packs of Taytulla oral birth control pills. Shares decline.

                                            Novo Nordisk's Oral Ozempic Positive in Diabetes Study

                                            Novo Nordisk's (NVO) oral formulation of Ozempic acts better in lowering blood sugar levels in adults with type II diabetes than Eli Lilly's Jardiance, in the second phase IIIa study, PIONEER 2.

                                              Swarup Gupta headshot

                                              Dow 30 Stock Roundup: GE's Transportation Unit to Merge With Wabtec, J&J & Glaxo's HIV Drug Gets EU Approval

                                              The Dow endured another volatile week marked by key geopolitical developments.

                                                FDA Confirms September Action Date for Teva's Migraine Drug

                                                Teva (TEVA) confirms that FDA has extended the goal date of the Biologics License Application (BLA) for fremanezumab to September from mid-June.

                                                  Merck's Keytruda Shows Survival Benefit in Squamous NSCLC

                                                  Merck's (MRK) Keytruda in combination with chemotherapy demonstrates better OS and PFS in first-line metastatic squamous NSCLC compared to chemotherapy alone.